|  |
| --- |
| **Supplementary Table 1.** Summary of G-banding, FISH, aCGH, multicolor flow cytometry, laboratory results, and clinical data |
| **Sample Date** | **G-banding**  | **FISH** | **aCGH** | **Flow cytometry** | **Morphology** | **Lab results** | **Conclusion** | **Treatment** |
| 28.09.09 | 47,XY,+idic(1)(p12),t(8;14)(q24;q32)[1]47,idem,del(15)(q24)[22]/46,XY[2]a | IgH con c-myc[134/200]Centromere 1x4, 1q12x4 | Gain: 1p12q44(120,15-246,85)Loss: 11q25(132,30-133,26),15q11.2(18,50-20,98),15q22q25(57,75-77,56) | Precursor B-ALL | Burkitt disease with precursor like cytochemistry. | Hgb 5.2 mmol/lWBC 6.4x109/lPlts 41x109/lU.A 0.40 U/lLDH 3345 U/l | PrecursorB-ALL changed toHigh risk B-cell ALL/BL | NOPHO ALL 2008 changed to B-NHL/B-ALL NOPHO 95 risk group III |
| 03.11.09 | n.d. | n.d. | n.d. | MRD <0.01% | CR |  | 1st CR |  |
| 01.12.09 | 46,XY[25] | t(8;14) negative | n.d. | MRD <0.01% | CR |  | CR |  |
| 28.12.09 | 46,XY[25] | t(8;14) negative | n.d. | MRD at 1% | CR |  | CR |  |
| 18.01.10 | 46,XY[25] | t(8;14) negative | n.d. | MRD <0.01% | CR |  | CR |  |
| 08.02.10 | 46,XY[25] | t(8;14) negative | n.d. | MRD <0.01% | CR |  | CR |  |
| 25.05.10 | 53,XY,+X,+Y,+idic(1)(p12),+6,+7,+8,t(8;14)(q24;q32)x2,+14,del(15)(q24)[25] | IgH con c-myc[120/200] | Gain: 1p12q44(120,15-246,85), X, 6, 7, 8, 14, 17q12(33,51-33,99), 20, 21q22.3(46,49-46,82)Loss: 11q25(132,30-133,26),15q11.2(18,50-20,98),15q22q25(57,75-77,56) | 1st relapse | 1st relapse | Hgb 8.2 mmol/lWBC 8.6x109/lPlts 36x109/lU.A <0.03 U/lLDH 2689 U/l | 1st relapse | B-NHL/B-ALL BFM 04 |
| 21.06.10 | n.d. | n.d. | n.d. | 8% pre-B-cells | 10% blasts |  | Partial remission |  |
| 29.06.10 | 53,XY,+X,+Y,+idic(1)(p12),+6,+7,+8,t(8;14)(q24;q32)x2,+14,del(15)(q24)[15]/46,XY[10] | IgH con -myc[26/200] | n.d. | 15% pre-B cells | CR |  | Progression |  |
| 20.07.10 | 46,XY[25] | IgH con c-myc[1/200] | n.d. | MRD at 4% | CR |  | Partial remission |  |
| 10.08.10 | 46,XY[25] | IgH con c-myc[4/200] | n.d. | MRD <0.01% | CR |  | 2nd CR |  |
| 30.08.10 | 53,XY,+X,+Y,+idic(1)(p12),+6,+7,+8,t(8;14)(q24;q32)x2,+14,del(15)(q24)[2]/46,XY[23] | IgH con c-myc[3/200] | n.d. | MRD at 0.3% | CR |  |  |  |
| 28.09.10 | 53,XY,+X,+Y,+idic(1)(p12),+6,+7,+8,der(8)t(8;14)(q24;q32)x2,+14,del(15)(q24),+mar1-2[cp 18]/46,XY[4] | IgH con c-myc[22/200] | n.d. | 2nd relapse11% pre-B cells | CR | Hgb 6.9 mmol/lWBC 2.1x109/lPlts 201x109/lLDH 240 U/l | 2nd relapse | Rituximab®-ICETriple ISP |
| 21.10.10 | 53,XY,+X,+Y,+idic(1)(p12),del(1)(q12),-5,+6,+7,+8,-8,der(8)t(8;14)(q24;q32)x2,+14,del(15)(q24),+20,+21,+mar1-2[cp 23]/46,XY[2] | IgH con c-myc[9/200] | n.d. | 13% pre-B cells | 2nd relapse |  |  |  |
| 08.11.10 | 46,XY[25] | IgH con c-myc[2/200] | n.d. | MRD at 0.5% | 3rd remission |  | 3rd remission |  |
| 08.12.10 |  |  |  |  |  |  |  | HSCT |
| 15.04.11 | 46,XY[25] | t(8;14) negative | n.d. | MRD at 0.5% | 3rd relapseHighly proliferative B-lymphoma | Hgb 6.1 mmol/lWBC 1.6x109/lPlts 33x109/lU.A 0.26 U/lLDH 765 U/l | 3rd relapse | Rituximab® monotherapy |
| 25.07.11 | 46,XY[25] | t(8;14) negative |  | MRD at 4% | CR |  | 4th CR |  |
| a The i(1)q(10) was revised to isodicentric chromosome 1, idic(1)p(12), due to aCGH and FISH results. MRD: minimal residual disease, CR: complete remission, Hgb: hemoglobulin, WBC: white blood cell count, Plts: platelets, U.A: uric acic, LDH: lactat dehydrogenase, Triple ISP: intraspinal instillation of Cytarabin, Metothrexat and Solu-Cortef, HSCT: hematopoietic stem cell transplantation |